Literature DB >> 7131300

Effect of altered disopyramide binding on its pharmacologic response in rabbits.

J D Huang, S Oie.   

Abstract

This study was undertaken to determine whether pharmacologic response to disopyramide is related to unbound or to total plasma concentration. Pharmacologic response, measured as changes in QRS duration of the EKG, was determined in rabbits at various steady-state concentrations of disopyramide under normal and altered plasma protein binding conditions. Plasma protein binding was increased by injection of 40 mg/kg of human glycoprotein fraction VI. The concentration-response curve for total concentration was displaced toward higher concentrations after increasing the plasma protein binding of disopyramide. The concentration-response curves obtained for unbound drug with and without the increased binding were superimposable. The displacement of the concentration-response curve for total drug was identical to the increase in concentration of the bound drug in plasma. These results demonstrate that the unbound concentrations of disopyramide in plasma are a better measure of the pharmacologic response than is the total plasma concentration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7131300

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP).

Authors:  J A Barnett; D E Brenner; P J Creaven; D Lalka
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

2.  Protein binding of cocaine in human serum.

Authors:  D J Edwards; S K Bowles
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

3.  Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism.

Authors:  Y Hashimoto; M Yasuhara; A Kamiya; K Okumura; R Hori
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

4.  Kinetics of ajmaline disposition and pharmacologic response in beagle dogs.

Authors:  M Yasuhara; Y Hashimoto; K Okumura; R Hori; T Sakurai; C Kawai
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

5.  Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.

Authors:  H Echizen; S Saima; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

6.  Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.

Authors:  K M Giacomini; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  In vitro protein binding of propafenone in normal and uraemic human sera.

Authors:  G L Chan; J E Axelson; J D Price; K M McErlane; C R Kerr
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.

Authors:  T Horiuchi; I Johno; T Hasegawa; S Kitazawa; M Goto; T Hata
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.